CN106420745A - 核受体结合剂在制备用于治疗肥胖症、纤维化和心血管疾病的药物中的应用 - Google Patents

核受体结合剂在制备用于治疗肥胖症、纤维化和心血管疾病的药物中的应用 Download PDF

Info

Publication number
CN106420745A
CN106420745A CN201610438738.5A CN201610438738A CN106420745A CN 106420745 A CN106420745 A CN 106420745A CN 201610438738 A CN201610438738 A CN 201610438738A CN 106420745 A CN106420745 A CN 106420745A
Authority
CN
China
Prior art keywords
another embodiment
compound
alkyl
hydrogen
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610438738.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·纳拉亚南
M·耶普鲁
J·T·多尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncternal Therapeutics Inc
Original Assignee
GTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTx Inc filed Critical GTx Inc
Publication of CN106420745A publication Critical patent/CN106420745A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CN201610438738.5A 2010-05-04 2011-05-04 核受体结合剂在制备用于治疗肥胖症、纤维化和心血管疾病的药物中的应用 Pending CN106420745A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/773,515 US9623021B2 (en) 2007-01-22 2010-05-04 Nuclear receptor binding agents
US12/773,515 2010-05-04
CN2011800327709A CN102970870A (zh) 2010-05-04 2011-05-04 核受体结合剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800327709A Division CN102970870A (zh) 2010-05-04 2011-05-04 核受体结合剂

Publications (1)

Publication Number Publication Date
CN106420745A true CN106420745A (zh) 2017-02-22

Family

ID=44904060

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610438738.5A Pending CN106420745A (zh) 2010-05-04 2011-05-04 核受体结合剂在制备用于治疗肥胖症、纤维化和心血管疾病的药物中的应用
CN2011800327709A Pending CN102970870A (zh) 2010-05-04 2011-05-04 核受体结合剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011800327709A Pending CN102970870A (zh) 2010-05-04 2011-05-04 核受体结合剂

Country Status (11)

Country Link
US (1) US9623021B2 (https=)
EP (1) EP2566330A4 (https=)
JP (2) JP5792799B2 (https=)
KR (1) KR20130061151A (https=)
CN (2) CN106420745A (https=)
AU (1) AU2011248154B2 (https=)
CA (1) CA2798259A1 (https=)
IL (1) IL222823A0 (https=)
MX (1) MX2012012777A (https=)
RU (1) RU2604666C2 (https=)
WO (1) WO2011140228A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
ES2475193T3 (es) * 2007-01-22 2014-07-10 Gtx, Inc. Agentes de unión al receptor nuclear
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US20140297314A1 (en) 2011-07-13 2014-10-02 Gino Tutera Systems and methods for calculating patient dosage
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
PT2872482T (pt) 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
HK1212448A1 (en) 2012-09-07 2016-06-10 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3010587A4 (en) * 2013-06-18 2017-04-12 Salk Institute for Biological Studies Methods of treating muscular dystrophy
PL229743B1 (pl) * 2013-07-30 2018-08-31 Narodowy Instytut Zdrowia Publicznego Panstwowy Zakl Higieny Nowe pochodne kwasu 3,4-dihydroizochinolino-3- karboks ylowego o właściwościach przeciwnowotworowych, sposób ich syntezy, kompozycje farmaceutyczne zawierające te pochodne oraz ich zastosowanie
DK3043865T3 (da) * 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
MA39838B1 (fr) 2014-04-04 2019-05-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
CN104776687B (zh) * 2014-09-05 2017-09-29 山东诚创医药技术开发有限公司 盐酸考来维仑聚合物的干燥方法
CN111557942B (zh) 2014-10-15 2023-10-03 科赛普特治疗学股份有限公司 使用糖皮质激素和盐皮质激素受体拮抗剂的脂肪肝疾病治疗
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
KR101800876B1 (ko) 2015-10-28 2017-11-27 전남대학교 산학협력단 신규한 디아릴이소퀴놀론 또는 디아릴이소퀴놀린 화합물 및 이를 포함하는 약제학적 조성물
WO2018034945A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
WO2018129470A1 (en) * 2017-01-09 2018-07-12 The Board Of Trustees Of The Leland Stanford Junior University Reversing deficient hedgehog signaling restores deficient skeletal regeneration
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11510944B2 (en) 2017-12-04 2022-11-29 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson disease
US11419832B2 (en) 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013699A1 (en) * 2001-05-25 2003-01-16 Davis Harry R. Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject
WO2006108107A1 (en) * 2005-04-06 2006-10-12 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
CN101641013A (zh) * 2007-01-22 2010-02-03 Gtx公司 核受体结合剂

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2848356A (en) * 1954-08-30 1958-08-19 Phillips Petroleum Co Fungicides, their preparation and use
CA1285951C (en) * 1985-10-28 1991-07-09 Raj N. Misra Naphthalenyl- and quinolinyl-amino substituted phenols
US4921941A (en) 1987-07-01 1990-05-01 Schering Corporation Orally active antiandrogens
DK33789A (da) 1988-01-27 1989-07-28 May & Baker Ltd Isoquinolinoner
US5177075A (en) * 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US4942163A (en) * 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
US5112869A (en) * 1989-04-04 1992-05-12 Sloan-Kettering Institute For Cancer Research Substituted 1-phenylnaphthalenes
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
PT590455E (pt) * 1992-09-28 2001-04-30 Hoechst Ag 1(2h)-isoquinolinas substituidas anti-arritmicas e cardioprotectoras processo para a sua preparacao medicamento contendo estes compostos e sua utilizacao para a preparacao de um medicamento para o combate de falhas cardiacas
DE4333761A1 (de) 1993-10-04 1995-04-06 Luitpold Pharma Gmbh Heterocyclische Carbamate, Verfahren zu ihrer Herstellung und Arzneimittel
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5719144A (en) * 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
IT1307327B1 (it) * 1995-09-12 2001-10-30 Smithkline Beecham Spa Derivati idroisochinolinici sostituiti
WO1997030047A1 (en) 1996-02-17 1997-08-21 Agrevo Uk Limited Fungicidal 1,2,4-oxadiazoles and analogues
SE9600769D0 (sv) * 1996-02-28 1996-02-28 Astra Ab Compounds useful as analgesic
JP3065949B2 (ja) 1996-09-13 2000-07-17 日本アンテナ株式会社 多周波用アンテナ
KR20000062358A (ko) 1996-12-27 2000-10-25 게리 디. 스트리트, 스티븐 엘. 네스비트 알츠하이머병 및 울병 치료용 ｎ-(피리디닐아미노)이소인돌린
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
WO1998038168A1 (en) 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
AU745790B2 (en) 1997-05-13 2002-03-28 Octamer, Inc. Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors
WO2000001389A1 (en) 1998-07-06 2000-01-13 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
JP2000072675A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd 医薬組成物
WO2000019994A1 (en) 1998-10-02 2000-04-13 Board Of Trustees Of The University Of Illinois Estrogen receptor ligands
US6486155B1 (en) * 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
AU766648B2 (en) * 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) * 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
ATE373642T1 (de) 1999-08-03 2007-10-15 Abbott Lab Kalium kanalaktivatoren
WO2001022960A1 (en) 1999-09-30 2001-04-05 Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Treatment of carbon monoxide poisoning
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
JP4331913B2 (ja) * 2000-02-14 2009-09-16 メルク エンド カムパニー インコーポレーテッド エストロゲンレセプターモデュレーター
US7214706B2 (en) * 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
KR20030027052A (ko) * 2000-08-23 2003-04-03 악조 노벨 엔.브이. 의료용 10-아릴-11Ｈ-벤조[ｂ]플루오렌 유도체 및 유사체
EP1322619B1 (en) * 2000-09-20 2008-01-23 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CA2321406A1 (en) 2000-09-29 2002-03-29 The Regents Of The University Of California Restoration of perturbed barrier function by application of antiandrogens
AU2002221269A1 (en) 2000-10-19 2002-04-29 Merck & Co., Inc. Estrogen receptor modulators
EP1339683B1 (en) 2000-11-27 2006-06-14 Merck & Co., Inc. Estrogen receptor modulators
WO2002046164A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic compounds
US20070004713A1 (en) 2000-12-07 2007-01-04 Bernard Barlaam Therapeutic benimidazole compounds
EP1345914A1 (en) 2000-12-22 2003-09-24 AstraZeneca AB Therapeutic compounds
WO2002058639A2 (en) 2001-01-23 2002-08-01 Merck & Co., Inc. Pyranoflavonoid compounds and their use as estrogen receptor modulators
WO2002072561A1 (en) * 2001-01-26 2002-09-19 Smithkline Beecham Corporation Piperazinyltriazines as estrogen receptor modulators
CN1500080A (zh) * 2001-02-02 2004-05-26 ����ҩƷ��ҵ��ʽ���� 稠合杂环化合物
EP1389238A2 (en) * 2001-04-27 2004-02-18 Bayer HealthCare AG Regulation of human prostaglandin-f synthase 1-like protein
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
WO2002091993A2 (en) 2001-05-10 2002-11-21 Merck & Co., Inc. Estrogen receptor modulators
JPWO2002094790A1 (ja) * 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
US20030119800A1 (en) * 2001-06-18 2003-06-26 Manolagas Stavros C. Bone anabolic compounds and methods of use
EP1414443B1 (en) 2001-08-01 2006-11-15 Merck & Co., Inc. BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES
WO2003015761A1 (en) 2001-08-13 2003-02-27 Merck & Co., Inc. Selective estrogen receptor modulators
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
EA007382B1 (ru) 2001-11-19 2006-10-27 Эли Лилли Энд Компани Замещенные бензопираны в качестве селективных агонистов бета-рецептора эстрогена
WO2003045930A1 (en) 2001-11-28 2003-06-05 Astrazeneca Ab Therapeutic compounds
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6903238B2 (en) * 2001-12-13 2005-06-07 Wyeth Substituted indenones as estrogenic agents
US6960607B2 (en) * 2001-12-13 2005-11-01 Wyeth Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents
EP1454898A4 (en) 2001-12-13 2006-12-13 Ajinomoto Kk NEW PHENYL ALANIDE DERIVATIVES
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
US7015219B2 (en) * 2001-12-19 2006-03-21 Bristol-Myers Squibb Company 3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
TW200408385A (en) 2001-12-21 2004-06-01 Akzo Nobel Nv Tetrahydrobenzfluorene derivatives
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists
AU2003211931A1 (en) 2002-02-13 2003-09-04 Takeda Chemical Industries, Ltd. Jnk inhibitor
AU2003212856A1 (en) 2002-03-01 2003-09-16 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
ATE481397T1 (de) * 2002-04-24 2010-10-15 Merck Sharp & Dohme Modulatoren des östrogenrezeptors
US20030220377A1 (en) * 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
CA2489906A1 (en) * 2002-06-06 2003-12-18 University Of Rochester Androgen receptor coregulators
DE10230381A1 (de) * 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US6893191B2 (en) 2002-07-19 2005-05-17 Creative Pultrusions, Inc. Wale and retaining wall system
MXPA05000983A (es) * 2002-07-24 2005-08-18 Kyorin Seiyaku Kk Derivados de 4-(aril substituido)-5-hidroxiisoquinolinona.
WO2004014378A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003264386A1 (en) 2002-09-10 2004-04-30 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
WO2004024184A1 (ja) 2002-09-11 2004-03-25 Takeda Pharmaceutical Company Limited 徐放性製剤
WO2004026290A1 (en) * 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
BR0314126A (pt) 2002-09-20 2005-06-28 Pfizer Prod Inc Ligandos de amida acìclica e sulfonamida para o receptor de estrogênio
JP2006518328A (ja) * 2002-10-15 2006-08-10 ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション 複素環選択的アンドロゲン受容体調節剤及びその使用方法
US7501412B2 (en) 2002-11-22 2009-03-10 Mitsubishi Tanabe Pharma Corporation Isoquinoline compounds and medicinal use thereof
ATE496893T1 (de) * 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
US7199110B2 (en) * 2002-12-30 2007-04-03 Purdue Research Foundation Method of treatment for spinal cord injury
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
EP1604983A4 (en) 2003-03-17 2008-06-25 Takeda Pharmaceutical Receptor Antagonists
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
ATE457308T1 (de) * 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
SI1626974T1 (sl) 2003-04-21 2009-02-28 Lilly Co Eli Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
ES2277273T3 (es) * 2003-05-16 2007-07-01 Wyeth Derivados de oxima de aril-carbaldehido, y su utilizacion como agentes estrogenicos.
US7250440B2 (en) * 2003-08-12 2007-07-31 Wyeth (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents
WO2005030791A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
CN1856473A (zh) * 2003-09-23 2006-11-01 默克公司 异喹啉酮钾通道抑制剂
WO2005030726A1 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
JP4879745B2 (ja) 2003-10-03 2012-02-22 ポートラ ファーマシューティカルズ， インコーポレイテッド 置換イソキノリノン
US20070072810A1 (en) * 2003-10-03 2007-03-29 Takeda Pharmaceutical Company, Limited Agent for treating diabetes
WO2005051972A1 (en) * 2003-11-24 2005-06-09 Merck & Co., Inc. Estrogen receptor modulators
WO2005097141A2 (en) * 2003-11-24 2005-10-20 Merck & Co., Inc. Estrogen receptor modulators
ES2307064T3 (es) * 2003-11-26 2008-11-16 Bayer Schering Pharma Aktiengesellschaft Prevencion y tratamiento de enfermedades cardiacas hipertensivas por los estrogenos selectivos 8beta-vinil-estra-1,3,5(10)-trien-3,17beta-diol y 17beta-fluor-9alfa-vinil-estra-1,3,5(10)-trien-3,16alfa-diol.
UA83416C2 (en) * 2004-02-13 2008-07-10 Баниу Фармасьютикал Ко., Лтд. Fused ring 4-oxopyrimidine derivative
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
WO2005099700A1 (en) 2004-04-06 2005-10-27 Merck & Co., Inc. Methods for the treatment of hypertension
CN1997618A (zh) * 2004-05-04 2007-07-11 阿卡迪亚医药公司 对雌激素受体具有活性的化合物
US20080015173A1 (en) 2004-06-10 2008-01-17 Blizzard Timothy A Estrogen Receptor Modulators
AU2005265174A1 (en) 2004-06-23 2006-01-26 Merck & Co., Inc. Estrogen receptor modulators
US20070203102A1 (en) * 2004-06-30 2007-08-30 Blizzard Timothy A Estrogen Receptor Modulators
JP2008505095A (ja) * 2004-07-01 2008-02-21 ワイス エストロゲンリガンドとしての四環式化合物
CN101072564A (zh) 2004-08-26 2007-11-14 恩希赛弗制药公司 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CA2578164A1 (en) * 2004-09-07 2006-03-16 Wyeth 6h-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents
US7354951B2 (en) * 2004-10-18 2008-04-08 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
AR051597A1 (es) 2004-11-01 2007-01-24 Merck & Co Inc Moduladores de los receptores de estrogeno
NZ555316A (en) 2004-12-09 2009-08-28 Merck & Co Inc Estrogen receptor modulators
US20060183652A1 (en) 2004-12-10 2006-08-17 Takashi Fujitsu Lubricating oil composition
RU2007129150A (ru) * 2004-12-31 2009-02-10 Авентис Фармасьютикалз Инк. (Us) Применение ряда фенилнафтильных соединений, которые не проявляют значительной аффинности в отношениях эстрогеновых рецепторов (er)
WO2006081152A2 (en) 2005-01-24 2006-08-03 Merck & Co., Inc. Estrogen receptor modulators
EP1853578A1 (en) 2005-02-15 2007-11-14 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-beta agonists
KR20070103456A (ko) * 2005-02-16 2007-10-23 와이어쓰 방사선- 또는 화학요법-유발 점막염 및 방사선 방광염용에스트로겐 수용체-β 선택적 아고니스트의 용도
US7482029B2 (en) * 2005-04-01 2009-01-27 Bionovo, Inc. Composition for treatment of menopause
US9763961B2 (en) * 2005-04-13 2017-09-19 City Of Hope Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use
US7456188B1 (en) 2005-04-28 2008-11-25 Bristol-Myers Squibb Company C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
KR100928954B1 (ko) * 2005-07-21 2009-11-30 리라이언스 라이프 사이언시스 프라이빗. 리미티드 리파제-중재된 질병을 치료하기 위한 화합물
US20070021495A1 (en) * 2005-07-25 2007-01-25 Katzenellenbogen John A Sulfonamides as selective estrogen receptor
KR101373535B1 (ko) * 2005-07-26 2014-03-12 사노피 Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
EP1943224B1 (en) 2005-10-05 2011-07-27 Merck Sharp & Dohme Corp. Estrogen receptor modulators
WO2007053353A2 (en) 2005-10-28 2007-05-10 Wyeth Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
CA2638040A1 (en) * 2006-02-09 2007-08-16 Micromet Ag Treatment of metastatic breast cancer
EP1987020B1 (en) 2006-02-15 2012-10-03 Sanofi Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
KR20080094699A (ko) * 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
EP1990335A4 (en) * 2006-03-02 2009-11-11 Astellas Pharma Inc 17-BETA-HSD-type-5 INHIBITOR
US8481529B2 (en) 2006-05-16 2013-07-09 The Arizona Board Of Regents On Behalf Of The University Of Arizona Combination cancer chemotherapy
JP2009541310A (ja) 2006-06-19 2009-11-26 アストラゼネカ・アクチエボラーグ イソキノリン誘導体およびサイトカイン仲介疾患の阻害剤としてのそれらの使用
US8318941B2 (en) * 2006-07-06 2012-11-27 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
JP2009545605A (ja) 2006-08-02 2009-12-24 ユニバーシティ オブ サザン カリフォルニア フィトエストロゲン製剤およびその使用
CA2606658A1 (en) * 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
GB0722779D0 (en) * 2007-11-20 2008-01-02 Sterix Ltd Compound
WO2009137543A2 (en) * 2008-05-06 2009-11-12 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment
WO2010096801A1 (en) 2009-02-23 2010-08-26 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2012006634A2 (en) 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013699A1 (en) * 2001-05-25 2003-01-16 Davis Harry R. Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject
WO2006108107A1 (en) * 2005-04-06 2006-10-12 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of steroid hormone nuclear receptors
CN101641013A (zh) * 2007-01-22 2010-02-03 Gtx公司 核受体结合剂

Also Published As

Publication number Publication date
AU2011248154A1 (en) 2012-11-29
JP2013525494A (ja) 2013-06-20
AU2011248154B2 (en) 2016-03-03
EP2566330A4 (en) 2013-11-06
JP2016006095A (ja) 2016-01-14
CN102970870A (zh) 2013-03-13
MX2012012777A (es) 2013-04-24
US20100267767A1 (en) 2010-10-21
RU2012151846A (ru) 2014-06-10
KR20130061151A (ko) 2013-06-10
US9623021B2 (en) 2017-04-18
RU2604666C2 (ru) 2016-12-10
WO2011140228A1 (en) 2011-11-10
IL222823A0 (en) 2012-12-31
EP2566330A1 (en) 2013-03-13
CA2798259A1 (en) 2011-11-10
JP5792799B2 (ja) 2015-10-14

Similar Documents

Publication Publication Date Title
CN106420745A (zh) 核受体结合剂在制备用于治疗肥胖症、纤维化和心血管疾病的药物中的应用
CN103432133B (zh) 核受体结合剂的用途
JP5913400B2 (ja) 核内受容体結合剤
US20170014401A1 (en) Nuclear receptor binding agents
JP2010523683A (ja) 糖尿病を治療するための選択的アンドロゲン受容体モジュレータ
JP2014518848A (ja) 糖尿病を治療するための選択的アンドロゲン受容体調節因子
CN101528214A (zh) 取代的n-酰基苯胺及其使用方法
AU2013219238B2 (en) Nuclear receptor binding agents
US9604931B2 (en) Nuclear receptor binding agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170222